Takezako, N., Shibayama, H., Handa, H., Hagiwara, S., Ozaki, S., Suzuki, K., . . . Iida, S. (2020). Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR. Int J Hematol.
Citação norma ChicagoTakezako, Naoki, et al. "Once-weekly Vs. Twice-weekly Carfilzomib Dosing in a Subgroup of Japanese Relapsed and Refractory Multiple Myeloma Patients From a Randomized Phase 3 Trial (A.R.R.O.W.) and Comparison With ENDEAVOR." Int J Hematol 2020.
Citação norma MLATakezako, Naoki, et al. "Once-weekly Vs. Twice-weekly Carfilzomib Dosing in a Subgroup of Japanese Relapsed and Refractory Multiple Myeloma Patients From a Randomized Phase 3 Trial (A.R.R.O.W.) and Comparison With ENDEAVOR." Int J Hematol 2020.